SINGAPORE, April 6, 2016 /CNW/ - Zecotek Photonics Inc.
(TSX-V: ZMS; Frankfurt: W1I.F,
OTCPK: ZMSPF), a developer of leading-edge photonics
technologies for industrial, healthcare and scientific markets, is
pleased to announce that its wholly owned division, Zecotek Imaging
Systems Pte. Ltd., has been granted its first patent in a series of
pending patents for its advanced formulation of its patented LFS
scintillation crystals. The patent is for multi-doped lutetium
oxide based scintillators having improved photonic properties.
"This patent protects our latest version of LFS scintillation
crystals which are the fastest, brightest and most advanced
scintillation crystals available to any OEM worldwide: the LFS-M,"
said Dr. A.F. Zerrouk, Chairman,
President, and CEO of Zecotek Photonics Inc. "Most crystals for
high resolution positron emission tomography (PET) imaging are
based on stoichiometric formulations of lutetium oxide with
silicate. While we also use lutetium oxide with silicate, our team
of Russian scientists use an off-stoichiometric process which
produces superior scintillators. No other company can produce
crystal like ours, and no other crystal can compete with the
LFS-M's speed and brightness. We have filed similar patent
applications in important jurisdictions around the world to
re-enforce and strengthen the existing patent for our line of LFS
scintillation crystals."
The new patent protects Zecotek's latest and most advanced
formulations of "off-stoichiometric" multi-doped lutetium oxide
based scintillation silicate crystals (LFS-M). Stoichiometric
formulations are known to have matching number of reactants which
produce full conversion of reactive groups into highly definable
cross-linked products. However, intentional deviation from
stoichiometric formulations, off-stoichiometric, enable the
creation of products containing predictable amounts of other
residual reactive groups which in turn enables the tuning of
mechanical properties. By going off-stoichiometric, Zecotek's
scientific team has produced the fastest, brightest and most
advanced LFS formulation available today.
About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS;
Frankfurt: W1I) is a photonics technology company developing
high-performance scintillation crystals, photo detectors, positron
emission tomography scanning technologies, 3D auto-stereoscopic
displays, 3D metal printing, and lasers for applications in
medical, high-tech and industrial sectors. Founded in 2004,
Zecotek operates three divisions: Imaging Systems, Optronics
Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on
building shareholder value by commercializing over 50 patented and
patent pending novel photonic technologies directly and through
strategic alliances, the European Organization for Nuclear Research
(Switzerland), Beijing
Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center
(South Korea). For more
information visit www.zecotek.com and follow @zecotek on
Twitter.
This press release may contain forward-looking statements
that are based on management's expectations, estimates, projections
and assumptions. These statements are not guarantees of future
performance and involve certain risks and uncertainties, which are
difficult to predict. Therefore, actual future results and trends
may differ materially from what may have been stated.
Neither the TSX Venture Exchange nor its Regulation Service
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of the content of this news release. If you would like to
receive news from Zecotek in the future please visit the corporate
website at www.zecotek.com.
SOURCE Zecotek Photonics Inc.